ARS Pharmaceuticals, Inc.

For the period ended Mar 31, 2026. Filed May 15, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 15, 2026

SPRY$3.57+13.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

	Three Months Ended March 31,
	2026	2025
Revenue:
Product revenue, net	$17,452	$7,763
Revenue under collaboration agreements	2,489	210
Revenue under supply agreements	2,740	—
Total revenue	22,681	7,973
Operating expenses:
Cost of goods sold (including related party amounts of $1,233 and $488, respectively)	6,286	1,094
Research and development (including related party amounts of $667 and $666, respectively)	4,336	2,952
Selling, general and administrative (including related party amounts of $135 and $124, respectively)	72,204	41,104
Total operating expenses	82,826	45,150
Loss from operations	(60,145)	(37,177)
Other income (expense), net:
Interest income	1,968	3,237
Interest expense (including related party amounts of $122 and $0, respectively)	(2,441)	—
Total other (expense) income, net	(473)	3,237
Net loss	(60,618)	(33,940)
Unrealized losses on available-for-sale securities	(221)	(148)
Comprehensive loss	$(60,839)	$(34,088)
Net loss per share, basic and diluted	$(0.61)	$(0.35)
Weighted-average shares outstanding used in computing net loss per share, basic and diluted	99,296,408	98,060,636

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.